Skip to Main Content
S. Karger AG
header search
Search
Advanced Search
Skip Nav Destination

Issues

Volume 13, Issue 4
August 2024
Issue Cover
All Issues
ISSN 2235-1795
EISSN 1664-5553

Liver Cancer 2024, Vol. 13, No. 4

Editorial

A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Subject Area: Gastroenterology , Oncology
Masatoshi Kudo
Liver Cancer (2024) 13 (4): 335–343. https://doi.org/10.1159/000539301
View articletitled, A Changing Role of Transarterial Chemoembolization in the Era of Immune Checkpoint Inhibitor plus Anti-VEGF/TKI plus Transarterial Chemoembolization: From Total Embolization to Partial Embolization (Immune Boost Transarterial Chemoembolization)
Open the PDF for in another window

Systematic Review

Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Subject Area: Gastroenterology , Oncology
Qi Du; Jia Yuan; Zhenggang Ren
Liver Cancer (2024) 13 (4): 344–354. https://doi.org/10.1159/000534446
View articletitled, Hepatocellular Carcinoma Patients with Hepatitis B Virus Infection Exhibited Favorable Survival from Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
Open the PDF for in another window

Review Article

Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)
Subject Area: Gastroenterology , Oncology
Xiufeng Liu; Yinying Lu; Weiping Zhou; Tao Peng; Jie Zhou; Huaqiang Bi; Feng Xia; Xiaoping Chen
Liver Cancer (2024) 13 (4): 355–375. https://doi.org/10.1159/000535496
View articletitled, Chinese Multidisciplinary Expert Consensus on Immune Checkpoint Inhibitor-Based Combination Therapy for Hepatocellular Carcinoma (2023 Edition)
Open the PDF for in another window
Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review
Subject Area: Gastroenterology , Oncology
Lorenzo Lani; Benedetta Stefanini; Franco Trevisani
Liver Cancer (2024) 13 (4): 376–388. https://doi.org/10.1159/000535497
View articletitled, Surveillance for Hepatocellular Carcinoma in Patients with Successfully Treated Viral Disease of the Liver: A Systematic Review
Open the PDF for in another window

Research Article

A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Subject Area: Gastroenterology , Oncology
Shukui Qin; Weijia Fang; Zhenggang Ren; Shuangyan Ou; Ho Yeong Lim; Feng Zhang; Kin Chung Lee; Hye Jin Choi; Jiandong Tong; Min Tao; Aibing Xu; Ashley Cheng; Chang-Hsien Lu; Chang-Fang Chiu; Mohamed Ibrahim Abdul Wahid; Shital Kamble; Josephine M. Norquist; Wenyan Zhong; Chen Li; Zhendong Chen
Liver Cancer (2024) 13 (4): 389–400. https://doi.org/10.1159/000535338
View articletitled, A Phase 3 Study of Pembrolizumab versus Placebo for Previously Treated Patients from Asia with Hepatocellular Carcinoma: Health-Related Quality of Life Analysis from KEYNOTE-394
Open the PDF for in another window
Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Subject Area: Gastroenterology , Oncology
Masatoshi Kudo; Kaoru Tsuchiya; Yu-Yun Shao; Richard S. Finn; Peter R. Galle; Michel Ducreux; Ann-Lii Cheng; Tatsuya Yamashita; Hironori Koga; Ryosuke Take; Kyoko Yamada; Takashi Asakawa; Yuki Nakagawa; Masafumi Ikeda
Liver Cancer (2024) 13 (4): 401–412. https://doi.org/10.1159/000535501
View articletitled, Impact of Bevacizumab Being Skipped due to Adverse Events of Special Interest for Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab: An Exploratory Analysis of the Phase III IMbrave150 Study
Open the PDF for in another window
Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study
Subject Area: Gastroenterology , Oncology
Heechul Nam; Jaejun Lee; Ji Won Han; Soon Kyu Lee; Hyun Yang; Hae Lim Lee; Pil Soo Sung; Hee Yeon Kim; Seok-Hwan Kim; Myeong Jun Song; Jung-Hyun Kwon; Chang Wook Kim; Soon Woo Nam; Si Hyun Bae; Jong Young Choi; Seung Kew Yoon; Jeong Won Jang
Liver Cancer (2024) 13 (4): 413–425. https://doi.org/10.1159/000535839
View articletitled, Analysis of Immune-Related Adverse Events of Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma: A Multicentre Cohort Study
Open the PDF for in another window
Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
Subject Area: Gastroenterology , Oncology
Gi-Ae Kim; Seogsong Jeong; Heejoon Jang; Dong Hyeon Lee; Sae Kyung Joo; Won Kim
Liver Cancer (2024) 13 (4): 426–437. https://doi.org/10.1159/000535943
View articletitled, Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatotic Liver Disease with Increased Alcohol Intake Increase the Risk of Developing Hepatocellular Carcinoma and Incident or Decompensated Cirrhosis: A Korean Nationwide Study
Open the PDF for in another window
A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
Subject Area: Gastroenterology , Oncology
Zhi-Mei Huang; Xue Han; Jian Wang; Ling Gu; Lu Tang; Shao-Yong Wu; Tian Di; Ying-Wen Hou; Wan Yee Lau; Yi-Quan Jiang; Jin-Hua Huang
Liver Cancer (2024) 13 (4): 438–450. https://doi.org/10.1159/000536518
View articletitled, A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
Open the PDF for in another window

Brief Report

A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Subject Area: Gastroenterology , Oncology
Masatoshi Kudo; Richard S. Finn; Masafumi Ikeda; Max W. Sung; Ari D. Baron; Takuji Okusaka; Masahiro Kobayashi; Hiromitsu Kumada; Shuichi Kaneko; Marc Pracht; Tim Meyer; Satoshi Nagao; Kenichi Saito; Kalgi Mody; Zahra Ramji; Leonid Dubrovsky; Josep M. Llovet
Liver Cancer (2024) 13 (4): 451–457. https://doi.org/10.1159/000535154
View articletitled, A Phase 1b Study of Lenvatinib plus Pembrolizumab in Patients with Unresectable Hepatocellular Carcinoma: Extended Analysis of Study 116
Open the PDF for in another window
High frequency of CTNNB1 variants associated with benign and malignant liver tumors in patients with Congenital Porto-Systemic Shunts
Lenvatinib plus Pembrolizumab Combined with Transarterial Chemoembolization in Intermediate-Stage Hepatocellular Carcinoma
Regorafenib for Hepatocellular Carcinoma in Real-World Practice (REFINE): A Prospective, Observational Study
Contents Vol. 13, 2024
  • Online ISSN 1664-5553
  • Print ISSN 2235-1795
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal